Literature DB >> 15787333

Mass screening of prostate cancer in Changchun City of China.

Xiaomeng Li1, Itiro Tsuji, Masaaki Kuwahara, Haifeng Zhang, Hongliang Wang, Ling Zhang, Guoyi Ji, Xuejian Zhao.   

Abstract

OBJECTIVES: Mass screening of prostate cancer in China had not been studied until now. To clarify the incidence of prostate cancer among the population of aged men in Changchun City of China, we performed a mass screening program for prostate cancer using prostate specific antigen (PSA).
METHODS: Men aged more than 50 years were examined by PSA, with a cut-off values 4.1 ng/ml. Subjects, whose serum PSA concentration was more than 4.1 ng/ml, were recommended to secondary examination of transrectal ultrasound-guided systematic six-sextant biopsy examination (TRUS-guided biopsy).
RESULTS: Between April 1998 and December 2000, in the urban area of Changchun City 4218 men over 50 years old were screened. As 190 men were found to have elevated PSA and 116 men underwent a TRUS-guided biopsy of the prostate, of whom 29 men were found to have cancer. In all, the age-adjusted PSA positive rate was 4.80%, cancer detection rate was 0.74%. The age-adjusted cancer detection rate was 0.78%. After adjusted for secondary examination rate, the cancer detection rate reached 1.28%. The cases of stage B with limited cancer within the prostate gland, accounted for 62% of 29 cancer cases. Stage B was much more detected (accounted for 60%) in the PSA range of 4.1-10.0 ng/ml. Stage C and D were much more detected (accounted for 85.71%) in the PSA range over 10.1 ng/ml, with a significant difference by Fisher exact test (P < 0.05). A significant correlation of age-adjusted PSA positive rate and age-adjusted cancer detection rate adjusted by secondary examination rate was showed in six groups of Community and Army, Factory, Corporation, Post and Telecom Office, Government and Academy, and University and Technical School (r = 0.898, P < 0.01). Both of the age-adjusted PSA positive rate and age-adjusted cancer detect rate of "Universities and Technical Schools" were significantly higher than that of "Factories" (chi2 test P < 0.05).
CONCLUSIONS: The prevalence of prostate cancer was not so low in Chinese people as expected. For 50 years or older men, cancer detection rate was 0.74%, The age-adjusted cancer detect rate was 0.78%. Much more early stage cancer could be detected in the screening using serum PSA. For the different company the detection rate of prostate cancer varied each other among the groups. Age-adjusted cancer detection rate in "Universities and Technical Schools" were significantly higher than in "Factories", suggesting environment factor or diet might be associated with the prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15787333     DOI: 10.1007/s11255-004-0842-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  27 in total

Review 1.  Detection of prostate cancer by prostate-specific antigen.

Authors:  S Egawa
Journal:  Biomed Pharmacother       Date:  2001-04       Impact factor: 6.529

2.  Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer.

Authors:  S Egawa; K Matsumoto; K Yoshida; M Iwamura; S Kuwao; K Koshiba
Journal:  Jpn J Clin Oncol       Date:  1998-11       Impact factor: 3.019

3.  Rising incidence of prostate cancer in Shanghai, China.

Authors:  A W Hsing; S S Devesa; F Jin; Y T Gao
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-01       Impact factor: 4.254

4.  [Clinical studies on endocrine therapy of prostatic carcinoma (2): Prognosis of patients with prostatic carcinoma given endocrine therapy, and analyses of causes of death and side effects of endocrine therapy].

Authors:  Y Kumamoto; T Tsukamoto; T Umehara; J Shimazaki; H Fuse; H Oshima; H Takeuchi; O Yoshida; K Okada; Y Saito
Journal:  Hinyokika Kiyo       Date:  1990-03

5.  Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations.

Authors:  K Ito; Y Kubota; K Suzuki; N Shimizu; Y Fukabori; K Kurokawa; K Imai; H Yamanaka
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

6.  Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.

Authors:  S J Jacobsen; S K Katusic; E J Bergstralh; J E Oesterling; D Ohrt; G G Klee; C G Chute; M M Lieber
Journal:  JAMA       Date:  1995-11-08       Impact factor: 56.272

7.  Systematic sextant biopsies in 651 patients referred for prostate evaluation.

Authors:  P Hammerer; H Huland
Journal:  J Urol       Date:  1994-01       Impact factor: 7.450

8.  A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii.

Authors:  R K Severson; A M Nomura; J S Grove; G N Stemmermann
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

9.  Screening for prostate cancer.

Authors:  D Pode; A Shapiro; P Lebensart; S Meretyk; G Katz; V Barak
Journal:  Isr J Med Sci       Date:  1995 Feb-Mar

10.  Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland.

Authors:  A Auvinen; T Tammela; U H Stenman; I Uusi-Erkkilä; J Leinonen; F H Schröder; M Hakama
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more
  7 in total

1.  Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor.

Authors:  Hao Wang; Jiang Li; Yang Gao; Ying Xu; Ying Pan; Ichiro Tsuji; Zi-Jie Sun; Xiao-Meng Li
Journal:  Asian J Androl       Date:  2010-05-03       Impact factor: 3.285

Review 2.  Prostate cancer: an emerging threat to the health of aging men in Asia.

Authors:  Ling Zhang; Bao-Xue Yang; Hai-Tao Zhang; Jin-Guo Wang; Hong-Liang Wang; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2011-05-09       Impact factor: 3.285

Review 3.  Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China.

Authors:  Ling Zhang; Shan Wu; Li-Rong Guo; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

4.  Clinical and pathological characteristics of screen-detected versus clinically diagnosed prostate cancer in Nanjing, China.

Authors:  LiXin Hua; Di Qiao; Bin Xu; NingHan Feng; Gong Cheng; JieXiu Zhang; NingHong Song; Wei Zhang; Jie Yang; JianGang Chen; YuanGeng Sui; HongFei Wu
Journal:  Med Oncol       Date:  2010-01-14       Impact factor: 3.064

5.  Prostate Cancer Screening Using Prostate-Specific Antigen Tests in a High-Risk Population in China: A Cost-Utility Analysis.

Authors:  Xiaojian Qin; Dingwei Ye; Chengyuan Gu; Yongqiang Huang; Weijie Gu; Bo Dai; Hailiang Zhang; Yao Zhu; Han Yang; Shuli Qu
Journal:  Curr Ther Res Clin Exp       Date:  2021-11-11

6.  China county-based prostate specific antigen screening for prostate cancer and a cost-effective analysis.

Authors:  Zhiguo Zhang; Guoshu Liang; Peng Zhang; Zhongqi Zhao; Zhongnan He; Fengzhen Luo; Zhenqing Chen; Zongke Yang; Zhijie Zhang; Tao Xia; Xin Liu; Yong Zhang; Wei Ye
Journal:  Transl Androl Urol       Date:  2021-10

7.  Different Trends in the Incidence and Mortality Rates of Prostate Cancer Between China and the USA: A Joinpoint and Age-Period-Cohort Analysis.

Authors:  Hairong He; Liang Liang; Didi Han; Fengshuo Xu; Jun Lyu
Journal:  Front Med (Lausanne)       Date:  2022-02-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.